

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Vutrisiran for treating hereditary transthyretin-related  
amyloidosis [ID5074]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes.

One stakeholder noted that there are over 100 mutations of the TTR gene, resulting in different presentations of the disease. Caucasian patients tend to have some mutations that result in more neuropathy and less cardiomyopathy (eg V30M), while patients from the black community tend to develop more cardiomyopathy and fewer neurological symptoms (eg V122I).

Second, it was highlighted that people with more advanced disability or those who live in remote areas have significant difficulties travelling for treatment. A treatment that minimises inconvenience has a higher value for these patients. It would be ideal if the treatment could be home delivered to the patients, in the same way patisiran and inotersen are administered at present, and if the cost of the delivery and administration could be included in the cost of the drug. This is especially important in the times of the coronavirus pandemic.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The prevalence of the disease is not an issue that can be addressed by committee evaluating this technology. It will consider any evidence presented about the clinical and cost effectiveness of the technology in any particular

Technology appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of vutrisiran for treating hereditary transthyretin-related amyloidosis [ID5074]

Issue date: September 2022

(sub)-groups. The committee will consider the implication of implementation and delivery at the appraisal committee meeting.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders identified.

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 8 September 2022